Previous 10 | Next 10 |
2023-09-26 11:20:50 ET More on GlycoMimetics Seeking Alpha’s Quant Rating on GlycoMimetics Historical earnings data for GlycoMimetics Financial information for GlycoMimetics GlycoMimetics: Q2 2024 Data Readout Makes This Worth A Look, But Cash Is A Pro...
GMI-1687, a highly potent E-selectin antagonist, is being developed as a potential point-of-care treatment for inflammatory diseases with initial focus on sickle cell disease (SCD) Single ascending dose study is expected to randomize approximately 40 healthy volunteers on GMI-1687 vs placebo ...
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present at the H.C. Wainwright 25 th Annual Global Investment Conference in New York, NY on Wednesday, September 13, 2023 at 11:30 a.m. ET. A live webcast of the presentation will be av...
2023-08-14 08:55:03 ET Summary GlycoMimetics is a biotech focused on developing novel agents that utilize carbohydrate chemistry for therapeutic effect. They have promising mid-stage clinical data and a projected critical data readout in late 2024. Operating costs and funding ...
2023-08-02 13:09:08 ET GlycoMimetics, Inc. (GLYC) Q2 2023 Earnings Conference Call August 2, 2023, 08:30 AM ET Company Participants Christian Dinneen-Long - General Counsel Harout Semerjian - CEO Edwin Rock - CMO Brian Hahn - CFO Conference Call Partici...
2023-08-02 07:06:55 ET GlycoMimetics press release ( NASDAQ: GLYC ): Q2 Non-GAAP EPS of -$0.13 beats by $0.04 . Cash and cash equivalents as of June 30, 2023 were $58.0 million. For further details see: GlycoMimetics Non-GAAP EPS of -$0.13 beats by $0.04
Topline results from pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) Acute Myeloid Leukemia (AML) expected by end of Q2 2024 after addition of time-based analysis option U.S. Food and Drug Administration (FDA) agrees to initial Pediatric Study Plan (iPSP) for uproleselan, an...
2023-08-01 13:51:55 ET GlycoMimetics ( NASDAQ: GLYC ) is scheduled to announce Q2 earnings results on Wednesday, August 2nd, before market open. The consensus EPS Estimate is -$0.17 and the consensus Revenue Estimate is $0.03M. Over the last 3 months, EPS estimates hav...
GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report second quarter 2023 financial results on Wednesday, August 2, 2023, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with...
2023-06-26 10:17:58 ET GlycoMimetics ( NASDAQ: GLYC ) has joined the Russell Microcap Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023. GLYC is +0.5% to $1.88 Source: Press Release ...
News, Short Squeeze, Breakout and More Instantly...
GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion leader event on Tuesday, June 4, 2024, at 8:30am ET to provide a comprehens...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38...